
    
      This is an open-label, single-sequence, multi-center trial with subjects previously diagnosed
      with primary immune deficiency. Subjects will be on IGIV until a steady state is reached at
      which time PK profiling during the IV phase will occur. Subjects will begin SC administration
      1 week following last IV dose and followed for a period of six months. PK profiling in SC
      phase will occur when subject reaches approximate steady-state on SC administration.
    
  